Singulex Secures Phase II SBIR from NCI to Develop Efficacy Assays for Cancer Drugs | GenomeWeb
NEW YORK (GenomeWeb) - Singulex said today that it has secured a Phase II Fast Track Small Business Innovation Research contract from the National Cancer Institute to develop biomarker assays to determine the effectiveness of potential cancer therapeutics.
The agreement extends a contract with NCI that Singulex originally signed in November 2007.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genetic history of HIV in the US, and more.

There are a few projects aimed at addressing the lack of diversity in genomic research, Technology Review reports.

A national assessment shows that US students lag in the sciences, but suggests that achievement gaps are narrowing.

Harvard's George Church discusses HGP-write with the Journal of the American Medical Association.